Total Liabilities Summary of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.'s latest annual total liabilities in 2023 was 124.94 Million EUR , down -57.76% from previous year.
Cosmo Pharmaceuticals N.V.'s latest quarterly total liabilities in 2024 Q2 was 132.86 Million EUR , down 0.0% from previous quarter.
Cosmo Pharmaceuticals N.V. reported annual total liabilities of 295.8 Million EUR in 2022, up 1.0% from previous year.
Cosmo Pharmaceuticals N.V. reported annual total liabilities of 292.88 Million EUR in 2021, up 49.4% from previous year.
Cosmo Pharmaceuticals N.V. reported quarterly total liabilities of 132.86 Million EUR for 2024 Q2, down 0.0% from previous quarter.
Cosmo Pharmaceuticals N.V. reported quarterly total liabilities of 124.94 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Total Liabilities of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Year	Total Liabilities	Total Liabilities Growth
2023	124.94 Million EUR	-57.76%
2022	295.8 Million EUR	1.0%
2021	292.88 Million EUR	49.4%
2020	196.03 Million EUR	2.41%
2019	191.42 Million EUR	5.86%
2018	180.83 Million EUR	549.14%
2017	27.85 Million EUR	-0.21%
2016	27.91 Million EUR	-18.6%
2015	34.29 Million EUR	-53.23%
2014	73.33 Million EUR	220.94%
2013	22.84 Million EUR	-16.13%
2012	27.24 Million EUR	86.55%
2011	14.6 Million EUR	-56.35%
2010	33.45 Million EUR	186.73%
2009	11.66 Million EUR	-19.68%
2008	14.52 Million EUR	20.26%
2007	12.08 Million EUR	-33.86%
2006	18.26 Million EUR	-33.77%
2005	27.58 Million EUR	13.3%
2004	24.34 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	132.86 Million EUR	6.34%
2024 Q2	132.86 Million EUR	0.0%
2023 Q4	124.94 Million EUR	0.0%
2023 Q1	298.65 Million EUR	0.96%
2023 Q2	298.65 Million EUR	0.0%
2023 FY	124.94 Million EUR	-57.76%
2023 Q3	124.94 Million EUR	-58.16%
2022 FY	295.8 Million EUR	1.0%
2022 Q4	295.8 Million EUR	0.0%
2022 Q2	296.03 Million EUR	0.0%
2022 Q1	296.03 Million EUR	1.07%
2022 Q3	295.8 Million EUR	-0.08%
2021 Q2	191.75 Million EUR	0.0%
2021 FY	292.88 Million EUR	49.4%
2021 Q3	292.88 Million EUR	52.74%
2021 Q1	191.75 Million EUR	-2.18%
2021 Q4	292.88 Million EUR	0.0%
2020 Q4	196.03 Million EUR	0.0%
2020 Q2	191.17 Million EUR	0.0%
2020 FY	196.03 Million EUR	2.41%
2020 Q1	191.17 Million EUR	-0.13%
2020 Q3	196.03 Million EUR	2.54%
2019 Q3	191.42 Million EUR	0.56%
2019 Q1	190.36 Million EUR	5.27%
2019 Q2	190.36 Million EUR	0.0%
2019 FY	191.42 Million EUR	5.86%
2019 Q4	191.42 Million EUR	0.0%
2018 Q1	23.22 Million EUR	-16.65%
2018 FY	180.83 Million EUR	549.14%
2018 Q4	180.83 Million EUR	0.0%
2018 Q3	180.83 Million EUR	678.78%
2018 Q2	23.22 Million EUR	0.0%
2017 Q4	27.85 Million EUR	0.0%
2017 FY	27.85 Million EUR	-0.21%
2017 Q1	26.55 Million EUR	-4.88%
2017 Q2	26.55 Million EUR	0.0%
2017 Q3	27.85 Million EUR	4.91%
2016 Q2	38.2 Million EUR	0.0%
2016 FY	27.91 Million EUR	-18.6%
2016 Q1	38.2 Million EUR	11.39%
2016 Q3	27.91 Million EUR	-26.93%
2016 Q4	27.91 Million EUR	0.0%
2015 Q4	34.29 Million EUR	0.0%
2015 Q3	34.29 Million EUR	-41.61%
2015 FY	34.29 Million EUR	-53.23%
2015 Q2	58.73 Million EUR	0.0%
2015 Q1	58.73 Million EUR	-19.91%
2014 Q4	73.33 Million EUR	0.0%
2014 Q2	24.61 Million EUR	0.0%
2014 Q1	24.61 Million EUR	7.71%
2014 FY	73.33 Million EUR	220.94%
2014 Q3	73.33 Million EUR	197.98%
2013 Q1	25 Million EUR	-8.2%
2013 FY	22.84 Million EUR	-16.13%
2013 Q4	22.84 Million EUR	0.0%
2013 Q3	22.84 Million EUR	-8.64%
2013 Q2	25 Million EUR	0.0%
2012 Q4	27.24 Million EUR	0.0%
2012 FY	27.24 Million EUR	86.55%
2012 Q2	15.48 Million EUR	0.0%
2012 Q3	27.24 Million EUR	75.99%
2011 Q2	32.27 Million EUR	0.0%
2011 Q4	14.6 Million EUR	0.0%
2011 FY	14.6 Million EUR	-56.35%
2010 Q2	36.73 Million EUR	0.0%
2010 Q4	33.45 Million EUR	0.0%
2010 FY	33.45 Million EUR	186.73%
2009 Q4	11.66 Million EUR	0.0%
2009 FY	11.66 Million EUR	-19.68%
2008 FY	14.52 Million EUR	20.26%
2007 FY	12.08 Million EUR	-33.86%
2006 FY	18.26 Million EUR	-33.77%
2005 FY	27.58 Million EUR	13.3%
2004 FY	24.34 Million EUR	0.0%

Peer Total Liabilities Comparison of Cosmo Pharmaceuticals N.V.

Name	Total Liabilities	Total Liabilities Difference
Relief Therapeutics Holding AG	24.16 Million CHF	-417.11%
Tecan Group AG	725.05 Million CHF	82.768%
Santhera Pharmaceuticals Holding AG	49.68 Million CHF	-151.467%
Basilea Pharmaceutica AG	183.29 Million CHF	31.833%
Bachem Holding AG	362.35 Million CHF	65.519%
Siegfried Holding AG	1.02 Billion CHF	87.791%
Molecular Partners AG	21.92 Million CHF	-469.922%

Global Stocks Search

Cosmo Pharmaceuticals N.V. (0RGI.L)

Total Liabilities Summary of Cosmo Pharmaceuticals N.V.

Annual Total Liabilities Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Total Liabilities of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Peer Total Liabilities Comparison of Cosmo Pharmaceuticals N.V.